At a glance
ClinicalIndex Comparison RecordN/AUnknown· 200 target
Drug / intervention
anti-PD-1 or anti-PD-L1 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open, Observational Clinical Study, 2-3 Cycles Treatment as Neoadjuvant Therapy for NSCLC With Stage IIB-IIIB
In Brief
An observational study evaluating anti-PD-1 or anti-PD-L1, EGFR-TKI, ALK inhibitor, ROS1 inhibitor, and 1 other intervention for Non Small Cell Lung Cancer. Targeting 200 participants across 1 site.
Detailed Summary
This study aims to investigate the efficacy and safety of targeted therapy and chemotherapy±immunotherapy as neoadjuvant therapy in stage IIB-IIIB NSCLC patients.（observational study）
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsNon Small Cell Lung Cancer
CountriesChina
Collaborators--
Timeline
N/AUnknownOverdue
20192020202120222023202420252026
Enrollment StartFeb 2019
First PostedDec 2019
Primary CompletionDec 2022
Study CompletionDec 2024
TodayJul 2026
First PostedDec 12, 2019
Enrollment StartFeb 25, 2019
Primary CompletionDec 31, 2022
Study CompletionDec 31, 2024
TodayJul 1, 2026
Enrollment to primary: 3.9 yearsPosted 6.6 years ago
Interventions
anti-PD-1 or anti-PD-L1drug
immunotherapy anti-PD-1 or anti-PD-L1
EGFR-TKI, ALK inhibitor, ROS1 inhibitordrug
targeted therapy EGFR-TKI, ALK inhibitor, ROS1 inhibitor
investigator decideddrug
chemotherapy